Mesa Laboratories financials
$130.98−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.1M | $63.7M | $65.1M | $60.7M | $59.5M | $62.1M | $62.8M | $57.8M | $58.2M | $58.9M | $53.5M | $53.2M |
| Gross profit | $39.0M | $42.2M | $41.8M | $37.3M | $36.9M | $38.4M | $39.8M | $35.5M | $37.2M | $36.6M | $33.4M | $32.1M |
| Gross margin | 64.9% | 66.2% | 64.2% | 61.5% | 62.0% | 61.8% | 63.3% | 61.3% | 64.0% | 62.1% | 62.5% | 60.4% |
| Operating income | $7.0M | $2.7M | $8.0M | $4.7M | $3.1M | $1.5M | $5.8M | $3.5M | $5.6M | -$271.3M | -$67.0K | -$60.0K |
| Net income | $2.8M | -$4.1M | $3.6M | $2.5M | $4.7M | -$7.1M | -$1.7M | $3.4M | $3.4M | -$254.6M | $2.1M | -$1.2M |
| Net margin | 4.7% | −6.5% | 5.6% | 4.1% | 8.0% | −11.4% | −2.7% | 5.9% | 5.8% | −432.2% | 4.0% | −2.3% |
| Diluted EPS | $0.49 | $-0.74 | $0.65 | $0.45 | $0.85 | $-1.33 | $-0.31 | $0.63 | $0.62 | $-47.24 | $0.39 | $-0.23 |
| EBITDA | $12.7M | $8.5M | $13.7M | $10.6M | $9.0M | $9.0M | $11.3M | $9.6M | $11.0M | $10.8M | $9.0M | $8.0M |
| Operating cash flow | $14.7M | $14.0M | $18.8M | $8.2M | $1.9M | $12.7M | $18.1M | $5.3M | $10.7M | $12.9M | $11.5M | $9.8M |
| Free cash flow | $14.2M | $13.5M | $18.0M | $7.1M | $884.0K | $11.9M | $17.3M | $3.5M | $9.9M | $12.3M | $10.4M | $9.1M |
| Diluted shares | 5.8M | 5.6M | 5.6M | 5.5M | 5.6M | 5.4M | 5.4M | 5.5M | 5.4M | 5.4M | 5.4M | 5.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.7M | $26.9M | $29.0M | $20.4M | $21.3M | $27.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $142.9M | $151.5M | $166.1M | $174.9M | $181.2M | $177.9M |
| Total assets | $419.2M | $427.7M | $434.8M | $430.4M | $435.7M | $433.3M |
| Total liabilities | $230.5M | $241.5M | $248.2M | $251.9M | $263.2M | $273.5M |
| Shareholders' equity | $188.8M | $186.2M | $186.7M | $178.5M | $172.5M | $159.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology